Allogene Therapeutics Inc(ALLO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.67 | Insider Own | 25.37% | Shs Outstand | 345.4M | Perf Week | -2.26% |
| Market Cap | 0.45B | Forward P/E | - | EPS next Y | -5.7% | Insider Trans | -0.08% | Shs Float | 257.8M | Perf Month | -19.75% |
| Enterprise Value | 0.20B | PEG | - | EPS next Q | -0.15 | Inst Own | 71.41% | Short Float | 20.71% | Perf Quarter | -34.01% |
| Income | -0.17B | P/S | 96.8 | EPS this Y | 30.88% | Inst Trans | 39.9% | Short Ratio | 8.88 | Perf Half Y | -38.39% |
| Sales | 0.00B | P/B | 1.03 | EPS next 5Y | 13.94% | ROA | -32.43% | Short Interest | 53.41M | Perf YTD | -5.11% |
| Book/sh | 1.26 | P/C | 1.35 | EPS past 3/5Y | 28.61% 16.08% | ROE | -42.39% | 52W High | -70.85% ($4.46) | Perf Year | 3.17% |
| Cash/sh | 0.96 | P/FCF | - | Sales past 3/5Y | - | ROIC | -32.67% | 52W Low | 25% ($1.04) | Perf 3Y | -48.62% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 40.16% | Gross Margin | -151.47% | Volatility(W/M) | 8.39% 6.18% | Perf 5Y | -92.42% |
| Dividend TTM | - | EV/Sales | 42.14 | Sales Y/Y TTM | -100% | Oper. Margin | -3886.14% | ATR (14) | 0.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.72 | EPS Q/Q | 44.26% | Profit Margin | -3566.68% | RSI (14) | 36.93 | Recom | 1.27 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.72 | Sales Q/Q | - | SMA20 | -4.17% ($1.36) | Beta | 0.73 | Target Price | $8.75 |
| Payout | - | Debt/Eq | 0.18 | Earnings | 2026/8/12 | SMA50 | -21.49% ($1.66) | Rel Volume | 1.72 | Prev Close | $1.23 |
| Employees | 152 | LT Debt/Eq | 0.16 | EPS/Sales Surpr. | 24.15% 186372% | SMA200 | -34.49% ($1.98) | Avg Volume(3M) | 6.02M | Price | $1.3 |
| IPO | 2018/10/11 | Option/Short | Yes/Yes | Trades | 19153 | Volume | 10,323,701 | Change | 5.69% |
🧬 Allogene Therapeutics (ALLO) is a US-based clinical-stage biotech company developing an allogeneic CAR-T cell therapy called "AlloCAR-T." It aims to overcome the limitations of conventional autologous CAR-T therapies—which use a patient's own cells—by creating an off-the-shelf cell therapy from healthy donor cells, targeting hematologic cancers and autoimmune diseases.
Over the past 1 year, on the lower side
71% below its 1-year high.
Traded more than usual. That is 172% of its average volume.
ALLO has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +30.9% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $9,680. Peers typically go for $1,237.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -92.4%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
20.7% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
WDNA WisdomTree BioRevolution Fund <0.01% 
BBC Virtus Biotech Clinical Trials ETF <0.01% 
QQQS Invesco NASDAQ Future Gen 200 ETF <0.01% 
XBI State Street SPDR S&P Biotech ETF <0.01% 
TMED T. Rowe Price Health Care ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
KRBN KraneShares Global Carbon Strategy ETF 137M 
KCCA Kraneshares California Carbon Allowance Strategy ETF 122M 
BTCK 7RCC Spot Bitcoin and Carbon Credit Futures ETF 2M It ranks #231 of 594 in the industry
Based on market cap of $449M.
PROK#229 ProKidney Corp $460M PER - 
EDIT#230 Editas Medicine Inc $453M PER - ALLO#231 Allogene Therapeutics Inc $449M PER - 
YDES#232 YD Bio Ltd $445M PER - 
MPLT#233 MapLight Therapeutics Inc $443M PER - 
FAQ
What kind of company is ALLO?
ALLO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ALLO?
The market cap of ALLO is approximately $449M, ranking 3,245 within its sector.
What is the 52-week high and low for ALLO?
ALLO has recorded a 52-week high of $4.46 and a low of $1.04.
